Therapeutic antibodies targeting protein conformational epitopes is crucial. The discovery of specific and functional antibodies against complex membrane proteins remains a major challenge in therapeutic development. It is largely due to difficulties in preserving native conformations required for functional antibody recognition. Conventional recombinant proteins are often insufficient to maintain critical conformational and quaternary epitopes, limiting conformation-driven antibody generation and screening. To address these limitations, Conigen Bioscience has developed innovative proprietary protein engineering technologies that recapitulate native cell-surface protein structures. The use of these novel proteins facilitates the discovery of antibodies that target conformational epitopes. These engineered proteins provide robust tools for conformation–driven antibody discovery to further advance therapeutic development.
